Tiburio Therapeutics

Tiburio is a clinical-stage biopharmaceutical company dedicated to advancing new therapies for rare neuroendocrine tumors and rare endocrine disorders with significant patient needs. Our pipeline consists of two clinical-stage compounds: TBR-760 for the treatment of non-functioning pituitary adenomas (NFPA), and TBR-065 for other rare endocrine disorders.